This is similar to the proportion of BP patients with diabetes mellitus reported in other settings for example Finland (34.0%), Korea (34.8%) and Turkey (31.7%).10,11,12 Gliptins, also known as dipeptidyl peptidase-4 inhibitors (DPP-4i), are associated with the development of BP.6,15 However, this class of glucose-lowering drug is not yet routinely available in our setting and none of the patients in this study had prior exposure to Gliptins. Here, DPP4 is linked to diabetes mellitus.